Autologous IL-10-Modified Dendritic Cells in Immune Therapy of Multiple Sclerosis: first analysis of results of clinical studies



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The search of effective therapy of multiple sclerosis CMS) that is the most common demyelinating disorder of the central nervous system affecting young people resulting in their disability is challenging. The cumulative experimental data as well as the clinical experience of dendritic cells usage in oncology facilitated a clinical investigation of applying autologous IL-^ О-modified dendritic cells in immune therapy of multiple sclerosis. At present the effects of this type of cell therapy in two patients with secondary progressive MS have been analysed. Autologous IL-10-modified dendritic cells injected subcutaneously into the patient's back in the dose of 3x10B are not shown to have produced any adverse effects. One patient had a rather distinct and significant clinical effect confirmed by MIR- and immunologic signs of increasing and then reducing the local inflammatory process activity in the brain. The immune system of patients with MS is found to respond whenever autologous IL-10-modified dendritic cells are administered unlike a clinical effect, with the response being rather complex, characterized by the total and relative increase of the peripheral blood regulatory T cell number. The data received allow considering further clinical investigations reasonable in order to clarify the indications for the given type of cell therapy in patients with multiple sclerosis.

About the authors

M M Odinak

B C Chirskiy

G N Bisaga

M V Pashchenkov

I A Baldueva

V M Moiseenko

T P Nekhaeva

N M Kalinina

N I Davydova

N V Bychkova

A V Pozdnyakov

MM Odinak

S.M. Kirov Military Medical Academy, Saint-Petersburg

S.M. Kirov Military Medical Academy, Saint-Petersburg

V S Chirsky

S.M. Kirov Military Medical Academy, Saint-Petersburg

S.M. Kirov Military Medical Academy, Saint-Petersburg

G N Bisaga

S.M. Kirov Military Medical Academy, Saint-Petersburg

S.M. Kirov Military Medical Academy, Saint-Petersburg

M V Pashchenkov

Research Institute of Immunology, Moscow

Research Institute of Immunology, Moscow

I A Baldueva

N.N. Petrov Research Institute of Oncology, Saint-Petersburg

N.N. Petrov Research Institute of Oncology, Saint-Petersburg

VM TL Nekhaeva

N.N. Petrov Research Institute of Oncology, Saint-Petersburg

N.N. Petrov Research Institute of Oncology, Saint-Petersburg

N M Kalinina

A.M. Nikiforov Russian Center of Emergency and Radiation Medicine, Saint-Petersburg

A.M. Nikiforov Russian Center of Emergency and Radiation Medicine, Saint-Petersburg

N I Davydova

A.M. Nikiforov Russian Center of Emergency and Radiation Medicine, Saint-Petersburg

A.M. Nikiforov Russian Center of Emergency and Radiation Medicine, Saint-Petersburg

N V Bychkova

A.M. Nikiforov Russian Center of Emergency and Radiation Medicine, Saint-Petersburg

A.M. Nikiforov Russian Center of Emergency and Radiation Medicine, Saint-Petersburg

A V Pozdnyakov

S.M. Kirov Military Medical Academy, Saint-Petersburg

S.M. Kirov Military Medical Academy, Saint-Petersburg

References

  1. Xiao B.G., Huang Y.M., Link Н. Tolerogenic Dendritic Cells: The Ins and Outs of Outcome J. Immunother. 200B; 29: 465-71.
  2. Stiive 0., Cravens P.D., EagarT.N. DNA-based vaccines: the future of multiple sclerosis therapy? Expert Rev. Neurother. 2008; 8: 351-60.
  3. Одинак M.M., Чирский B.C., Бисага Т.Н. и др. Аутогенные IL-1 О-модифицированные дендритные клетки в иммунотерапии рассеянного склероза: первый клинический опыт. Клеточная трансплантология и тканевая инженерия. 2008; 4: 60-5.
  4. Duan R.S., Link Н., Xiao B.G. Long-term effects of IFN-y, IL-10 and TGF-p-modulated dendritic cells on immune response in Lewis rats. J. Clin. Immunol. 2005; 25: 50-6.
  5. Авторское свидетельство на изобретение № 2203683 «Способ иммунотерапии костно-мозговыми дендритными клетками больных солидными опухолями» [авторы: Моисеенко В.М., Балдуева И.А., Орлова Р.В., Семенова А.И.).
  6. Балдуева И.А. Противоопухолевые вакцины. Практическая онкология. 2003; 3: 157-66.
  7. Моисеенко В.М., Балдуева И.А., Данилова А.Б. и др. Шестилетний опыт вакцинотерапии злокачественных опухолей. Мед.иммунология 2004; 3-5: 458.
  8. Steinbrink К., Wolfl М., Jonuleit Н. et al. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 1ЭЭ7; 159: 4772-80.
  9. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003; 21: 685-711.
  10. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002; 23: 445-9.
  11. Taams L.S., Akbar A.N. Peripheral generation and function of CD4+CD25+ regulatory T cells. Curr. Top Microbiol. Immunol. 2005; 293: 115-31.
  12. Serody J.S., Collins E.J., Tisch R.M. et al. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J. Immunol. 2000; 164: 4961-7.
  13. Corinti S., Albanesi C, laSalaA. etal. Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. 2001; 166: 4312-8.
  14. Rutella S., Bonanno G., Pierelli L. et al. Granulocyte colonystimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur. J. Immunol. 2004; 34: 1291-302.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies